| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
101,580,000 |
| Market
Cap: |
1.07(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.28 - $27.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 12.2 |
| Insider 6 Months : 14.2 |
| Insider 3/6 Months : 26.8 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Intellia Therapeutics is a genome editing company focused on developing therapeutics using CRISPR/Cas9 technology. CRISPR/Cas9, an acronym for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9), is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To realize the transformative potential of CRISPR/Cas9-based technologies, Co. is building a range of genome editing company, by utilizing its modular platform, to advance in vivo and ex vivo therapies for diseases with high unmet need.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
150,000 |
250,000 |
250,000 |
250,000 |
| Total Buy Value |
$1,402,500 |
$2,405,500 |
$2,405,500 |
$2,405,500 |
| Total People Bought |
1 |
2 |
2 |
2 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
171,983 |
181,347 |
191,747 |
266,827 |
| Total Sell Value |
$1,608,524 |
$1,746,198 |
$1,844,328 |
$2,856,499 |
| Total People Sold |
7 |
7 |
9 |
12 |
| Total Sell Transactions |
8 |
11 |
19 |
32 |
| End Date |
2025-10-11 |
2025-07-10 |
2025-01-09 |
2024-01-10 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dube Michael P |
VP, Chief Accounting Officer |
• – – |
2026-01-05 |
4 |
S |
$9.21 |
$27,529 |
D/D |
(2,989) |
52,277 |
|
-8% |
|
| Lebwohl David |
EVP, Chief Medical Officer |
• – – |
2026-01-05 |
4 |
S |
$9.21 |
$109,627 |
D/D |
(11,903) |
121,249 |
|
-8% |
|
| Cohen Fred E |
|
– • – |
2026-01-05 |
4 |
B |
$9.35 |
$1,402,500 |
D/D |
150,000 |
207,453 |
0.01 |
8% |
|
| Clark Eliana |
EVP, Chief Technical Officer |
• – – |
2026-01-05 |
4 |
S |
$9.21 |
$87,633 |
D/D |
(9,515) |
87,118 |
|
-8% |
|
| Dulac Edward J Iii |
EVP, Chief Financial Officer |
• – – |
2026-01-05 |
4 |
S |
$9.21 |
$58,751 |
D/D |
(6,379) |
99,683 |
|
-8% |
|
| Leonard John M. |
President and CEO |
• • – |
2026-01-05 |
4 |
S |
$9.21 |
$314,485 |
D/D |
(34,146) |
1,013,339 |
|
-8% |
|
| Basta James |
EVP, General Counsel |
• – – |
2026-01-05 |
4 |
S |
$9.21 |
$95,756 |
D/D |
(10,397) |
101,528 |
|
-8% |
|
| Schultes Birgit C |
EVP, Chief Scientific Officer |
• – – |
2026-01-05 |
4 |
S |
$9.21 |
$78,359 |
D/D |
(8,508) |
98,533 |
|
-8% |
|
| Leonard John M. |
President and CEO |
• • – |
2025-12-12 |
4 |
OE |
$6.83 |
$58,444 |
D/D |
8,557 |
1,047,485 |
|
- |
|
| Leonard John M. |
President and CEO |
• • – |
2025-12-11 |
4 |
AS |
$9.47 |
$836,384 |
D/D |
(88,146) |
1,038,928 |
|
-4% |
|
| Leonard John M. |
President and CEO |
• • – |
2025-12-11 |
4 |
OE |
$6.83 |
$341,220 |
D/D |
49,959 |
1,127,074 |
|
- |
|
| Schultes Birgit C |
EVP, Chief Scientific Officer |
• – – |
2025-10-01 |
4 |
S |
$17.38 |
$539 |
D/D |
(31) |
105,184 |
|
46% |
|
| Dube Michael P |
VP, Chief Accounting Officer |
• – – |
2025-10-01 |
4 |
S |
$17.38 |
$32,518 |
D/D |
(1,871) |
55,266 |
|
46% |
|
| Chase William J |
|
– • – |
2025-08-20 |
4 |
B |
$10.03 |
$1,003,000 |
D/D |
100,000 |
134,693 |
0.01 |
-10% |
|
| Dulac Edward J Iii |
EVP, Chief Financial Officer |
• – – |
2025-07-23 |
4 |
S |
$14.02 |
$104,617 |
D/D |
(7,462) |
106,062 |
|
37% |
|
| Dube Michael P |
VP, Chief Accounting Officer |
• – – |
2025-07-02 |
4 |
S |
$9.95 |
$24,905 |
D/D |
(2,503) |
57,137 |
|
11% |
|
| Clark Eliana |
EVP, Chief Technical Officer |
• – – |
2025-07-01 |
4 |
S |
$9.82 |
$10,036 |
D/D |
(1,022) |
95,369 |
|
-25% |
|
| Goodman Jesse |
|
– • – |
2025-07-01 |
4 |
AS |
$9.23 |
$14,279 |
D/D |
(1,547) |
24,359 |
|
25% |
|
| Goodman Jesse |
|
– • – |
2025-06-30 |
4 |
AS |
$9.56 |
$14,789 |
D/D |
(1,547) |
25,906 |
|
45% |
|
| Keresty Georgia |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
31,883 |
|
- |
|
| Bhanji Muna |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
27,203 |
|
- |
|
| Goodman Jesse |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
27,453 |
|
- |
|
| Verwiel Frank |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
25,948 |
|
- |
|
| Chase William J |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
34,693 |
|
- |
|
| Goff Brian |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
23,409 |
|
- |
|
306 Records found
|
|
Page 1 of 13 |
|
|
0.39 (3.85%) 
